JPS6157288B2 - - Google Patents
Info
- Publication number
- JPS6157288B2 JPS6157288B2 JP57038238A JP3823882A JPS6157288B2 JP S6157288 B2 JPS6157288 B2 JP S6157288B2 JP 57038238 A JP57038238 A JP 57038238A JP 3823882 A JP3823882 A JP 3823882A JP S6157288 B2 JPS6157288 B2 JP S6157288B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- culture medium
- membrane
- substance
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000004027 cell Anatomy 0.000 claims description 155
- 239000002775 capsule Substances 0.000 claims description 83
- 239000012528 membrane Substances 0.000 claims description 83
- 239000001963 growth medium Substances 0.000 claims description 82
- 238000000034 method Methods 0.000 claims description 50
- 239000000126 substance Substances 0.000 claims description 49
- 230000035699 permeability Effects 0.000 claims description 32
- 229920000642 polymer Polymers 0.000 claims description 22
- 102000014150 Interferons Human genes 0.000 claims description 21
- 108010050904 Interferons Proteins 0.000 claims description 21
- 229940079322 interferon Drugs 0.000 claims description 18
- 229920001971 elastomer Polymers 0.000 claims description 17
- 239000005060 rubber Substances 0.000 claims description 17
- 125000000129 anionic group Chemical group 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 238000005538 encapsulation Methods 0.000 claims description 10
- 230000035899 viability Effects 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 239000011159 matrix material Substances 0.000 claims description 9
- 235000015097 nutrients Nutrition 0.000 claims description 9
- 125000002091 cationic group Chemical group 0.000 claims description 8
- 150000001768 cations Chemical class 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 7
- 210000004408 hybridoma Anatomy 0.000 claims description 6
- 239000003094 microcapsule Substances 0.000 claims description 6
- 230000004060 metabolic process Effects 0.000 claims description 5
- 230000011278 mitosis Effects 0.000 claims description 5
- 239000002344 surface layer Substances 0.000 claims description 5
- 238000004132 cross linking Methods 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 239000006143 cell culture medium Substances 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 230000003248 secreting effect Effects 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 30
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 16
- 238000004113 cell culture Methods 0.000 description 16
- 239000012091 fetal bovine serum Substances 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 239000000499 gel Substances 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000006698 induction Effects 0.000 description 9
- 230000002503 metabolic effect Effects 0.000 description 9
- 239000006285 cell suspension Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 7
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 229920000669 heparin Polymers 0.000 description 7
- 229960002897 heparin Drugs 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 235000010413 sodium alginate Nutrition 0.000 description 7
- 239000000661 sodium alginate Substances 0.000 description 7
- 229940005550 sodium alginate Drugs 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 108010039918 Polylysine Proteins 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 229920000656 polylysine Polymers 0.000 description 6
- 239000003352 sequestering agent Substances 0.000 description 6
- 239000001509 sodium citrate Substances 0.000 description 6
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 6
- 108010017384 Blood Proteins Proteins 0.000 description 5
- 102000004506 Blood Proteins Human genes 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000004017 serum-free culture medium Substances 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 235000011148 calcium chloride Nutrition 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 239000004490 capsule suspension Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910001413 alkali metal ion Inorganic materials 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 150000001518 atomic anions Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- -1 hydrogen ions Chemical class 0.000 description 2
- 239000000367 immunologic factor Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 229940123752 RNA synthesis inhibitor Drugs 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229920001284 acidic polysaccharide Polymers 0.000 description 1
- 150000004805 acidic polysaccharides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 108010067755 dinitrophenyl-bovine serum albumin Proteins 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 238000012787 harvest procedure Methods 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000000879 imine group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0012—Cell encapsulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
- A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
- C12N2533/32—Polylysine, polyornithine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/74—Alginate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24358381A | 1981-03-13 | 1981-03-13 | |
| US243583 | 1994-05-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5816693A JPS5816693A (ja) | 1983-01-31 |
| JPS6157288B2 true JPS6157288B2 (fr) | 1986-12-06 |
Family
ID=22919321
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57038238A Granted JPS5816693A (ja) | 1981-03-13 | 1982-03-12 | 細胞により産生される物質の製造方法 |
| JP60184995A Granted JPS6188893A (ja) | 1981-03-13 | 1985-08-22 | 細胞により産生される物質の製造方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60184995A Granted JPS6188893A (ja) | 1981-03-13 | 1985-08-22 | 細胞により産生される物質の製造方法 |
Country Status (11)
| Country | Link |
|---|---|
| JP (2) | JPS5816693A (fr) |
| BE (1) | BE892479A (fr) |
| CA (1) | CA1172961A (fr) |
| CH (1) | CH654328A5 (fr) |
| DE (1) | DE3209127A1 (fr) |
| DK (1) | DK112282A (fr) |
| FR (1) | FR2503183B1 (fr) |
| GB (1) | GB2094833B (fr) |
| IT (1) | IT1150682B (fr) |
| NO (1) | NO163060C (fr) |
| SE (1) | SE454780B (fr) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO161446C (no) * | 1981-03-13 | 1989-08-16 | Damon Biotech Inc | Fremgangsmaate for dyrking av celler som er avhengige av forankring. |
| US4582799A (en) * | 1983-04-15 | 1986-04-15 | Damon Biotech, Inc. | Process for recovering nonsecreted substances produced by cells |
| CA1196862A (fr) * | 1983-06-01 | 1985-11-19 | Anthony M.F. Sun | Microencapsulement de cellules et de tissus vivants |
| JPS6025929A (ja) * | 1983-07-20 | 1985-02-08 | ザ・スト−ル・リサ−チ・アンド・デイベロツプメント・コ−ポレ−シヨン | カプセル化細胞、その製造方法および用途 |
| JPS60141281A (ja) * | 1983-12-28 | 1985-07-26 | Meiji Milk Prod Co Ltd | 菌体顆粒の製造方法及び装置 |
| DE3575375D1 (de) * | 1984-02-15 | 1990-02-22 | Massachusetts Inst Technology | Verfahren zur verkapselung und systeme mit verkapseltem aktivmaterial. |
| JPS60175539A (ja) * | 1984-02-23 | 1985-09-09 | Snow Brand Milk Prod Co Ltd | カプセル体およびその製造法 |
| US6686455B1 (en) | 1984-07-05 | 2004-02-03 | Genentech, Inc. | Tumor necrosis factor |
| GR851626B (fr) * | 1984-07-05 | 1985-11-26 | Genentech Inc | |
| US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
| CA1241598A (fr) * | 1984-07-11 | 1988-09-06 | Connaught Laboratories Limited | Generation de gouttelettes |
| EP0199362A3 (fr) * | 1985-04-26 | 1987-10-07 | Massachusetts Institute Of Technology | Système et dispositif pour la libération retardée et par à-coups de substances biologiquement actives |
| CA1265443A (fr) * | 1985-09-18 | 1990-02-06 | Elieser Gorelik | Epreuves de sensibilite aux agents chimiotherapeutiques |
| DE3534983A1 (de) * | 1985-10-01 | 1987-04-02 | Sturge John & E Ltd | Komplexe immobilisierte biokatalysatoren sowie ihre herstellung und anwendung |
| JPS62166891A (ja) * | 1986-01-20 | 1987-07-23 | Snow Brand Milk Prod Co Ltd | 細胞培養による有用物質の製造方法 |
| EP0259365A1 (fr) * | 1986-01-23 | 1988-03-16 | Ltl Associates | Membranes covalentes |
| DE3615043A1 (de) * | 1986-05-03 | 1987-11-05 | Hoechst Ag | Verfahren zur verkapselung von biologisch aktivem material |
| IL79052A0 (en) * | 1986-06-06 | 1986-11-30 | Univ Ramot | Device and process for production of alginate-shell beads containing biologically active material |
| JP2530690Y2 (ja) * | 1986-08-28 | 1997-03-26 | カシオ計算機株式会社 | 電子楽器 |
| US5420242A (en) * | 1986-10-22 | 1995-05-30 | Kaare M. Gautvik | Production of human parathyroid hormone from microorganisms |
| US5010010A (en) * | 1986-10-22 | 1991-04-23 | Selmer-Sande, A.S. | Production of human parathyroid hormone from microorganisms |
| JP2777132B2 (ja) | 1986-10-22 | 1998-07-16 | カーレ・エンム・ガウトビク | 微生物によるヒト副甲状腺ホルモンの生産 |
| EP0355112A1 (fr) * | 1987-04-22 | 1990-02-28 | Michael Bay | Procedes de culture de cellules, et produits |
| JPS6414225U (fr) * | 1987-07-15 | 1989-01-25 | ||
| JPH025797U (fr) * | 1988-06-23 | 1990-01-16 | ||
| WO1991010470A1 (fr) * | 1990-01-08 | 1991-07-25 | Brown University Research Foundation | Dispositifs et procedes d'apport ameliore de facteurs actifs |
| US5800829A (en) * | 1991-04-25 | 1998-09-01 | Brown University Research Foundation | Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core |
| JP4215273B2 (ja) * | 1991-04-25 | 2009-01-28 | ブラウン ユニヴァーシティ リサーチ ファンデーション | 選択された治療物質放出用の移植可能で生体適合性の免疫遮断性ビークル |
| DE4229526B4 (de) * | 1992-09-07 | 2006-02-16 | Schrezenmeir, Jürgen, Dr. | Vorrichtung zur Aufnahme und zum Einbringen von biologisch aktiven Geweben oder Zellen in den menschlichen Körper |
| US5908623A (en) * | 1993-08-12 | 1999-06-01 | Cytotherapeutics, Inc. | Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
| EP1179350A3 (fr) * | 1993-08-12 | 2003-01-02 | Cytotherapeutics, Inc. | Système cellulaire encapsulé pour implantation dans le SNC hunain |
| US5550050A (en) * | 1994-04-15 | 1996-08-27 | Cytotherapeutics, Inc. | Method for implanting encapsulated cells in a host |
| DE4426396A1 (de) * | 1994-07-26 | 1996-02-01 | Ulrich Prof Dr Zimmermann | Verfahren zur Herstellung konzentrierter Lösungen von mikroverkapselten Zellen oder von suspendierten Wirkstoffen in mikroverkapselter Form |
| US5916790A (en) * | 1995-03-03 | 1999-06-29 | Metabolex, Inc. | Encapsulation compositions, and methods |
| SE9702401D0 (sv) | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
| KR102007997B1 (ko) * | 2011-02-07 | 2019-08-07 | 라이프 테크놀로지스 코포레이션 | 감수성 화합물을 안정화시키는 조성물 및 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4324683A (en) * | 1975-08-20 | 1982-04-13 | Damon Corporation | Encapsulation of labile biological material |
| US4352883A (en) * | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
| NO158284C (no) * | 1981-03-13 | 1988-08-17 | Damon Biotech Inc | Fremgangsmaate for selektiv oppbrytning av en permeabel membran. |
| NO161446C (no) * | 1981-03-13 | 1989-08-16 | Damon Biotech Inc | Fremgangsmaate for dyrking av celler som er avhengige av forankring. |
-
1982
- 1982-03-11 NO NO820794A patent/NO163060C/no unknown
- 1982-03-12 IT IT20140/82A patent/IT1150682B/it active
- 1982-03-12 FR FR8204242A patent/FR2503183B1/fr not_active Expired
- 1982-03-12 JP JP57038238A patent/JPS5816693A/ja active Granted
- 1982-03-12 CA CA000398218A patent/CA1172961A/fr not_active Expired
- 1982-03-12 CH CH1575/82A patent/CH654328A5/de not_active IP Right Cessation
- 1982-03-12 SE SE8201554A patent/SE454780B/sv not_active IP Right Cessation
- 1982-03-12 DE DE19823209127 patent/DE3209127A1/de active Granted
- 1982-03-12 BE BE0/207559A patent/BE892479A/fr not_active IP Right Cessation
- 1982-03-12 GB GB8207309A patent/GB2094833B/en not_active Expired
- 1982-03-12 DK DK112282A patent/DK112282A/da not_active Application Discontinuation
-
1985
- 1985-08-22 JP JP60184995A patent/JPS6188893A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| NO163060B (no) | 1989-12-18 |
| JPS5816693A (ja) | 1983-01-31 |
| CH654328A5 (de) | 1986-02-14 |
| FR2503183A1 (fr) | 1982-10-08 |
| GB2094833B (en) | 1984-06-20 |
| BE892479A (fr) | 1982-07-01 |
| NO163060C (no) | 1990-03-28 |
| NO820794L (no) | 1982-09-14 |
| JPS6188893A (ja) | 1986-05-07 |
| GB2094833A (en) | 1982-09-22 |
| FR2503183B1 (fr) | 1985-11-08 |
| SE8201554L (sv) | 1982-09-14 |
| IT1150682B (it) | 1986-12-17 |
| DE3209127C2 (fr) | 1988-02-04 |
| CA1172961A (fr) | 1984-08-21 |
| JPS6244919B2 (fr) | 1987-09-24 |
| IT8220140A0 (it) | 1982-03-12 |
| DK112282A (da) | 1982-09-14 |
| SE454780B (sv) | 1988-05-30 |
| DE3209127A1 (de) | 1982-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6157288B2 (fr) | ||
| US4409331A (en) | Preparation of substances with encapsulated cells | |
| US4495288A (en) | Method of culturing anchorage dependent cells | |
| US4407957A (en) | Reversible microencapsulation of a core material | |
| JP3524096B2 (ja) | 水性媒体において膜をゲル化粒子の少なくとも表面に形成するためのエステル化多糖とポリアミンとの間のアシル交換反応の使用、それにより生成した粒子、それらの製造方法及び前記粒子を含有する組成物 | |
| US4352883A (en) | Encapsulation of biological material | |
| US4391909A (en) | Microcapsules containing viable tissue cells | |
| CA1215922A (fr) | Microencapsulation de cellules et de tissus vivants | |
| EP0127713B1 (fr) | Micro-encapsulation de tissu vivant et de cellules | |
| US5871985A (en) | Particulate non cross-linked chitosan core matrices for encapsulated cells | |
| JPS6152737B2 (fr) | ||
| JPS6038111B2 (ja) | 固定依存性細胞の培養法 | |
| JPS61189218A (ja) | カプセル封入方法 | |
| AU687359B2 (en) | Chitosan matrices for encapsulated cells | |
| EP0127989A2 (fr) | Micro-encapsulation de tissu vivant et de cellules | |
| US4582799A (en) | Process for recovering nonsecreted substances produced by cells | |
| Kampf | The use of polymers for coating of cells | |
| JPS6238327B2 (fr) | ||
| CA1280381C (fr) | Inclusion de cellules dependant d'un support | |
| JPH0533981B2 (fr) | ||
| JPH0685711B2 (ja) | 細胞の繁殖方法 | |
| JPH048034B2 (fr) |